What are the major factors driving the growth of the pulmonary fibrosis treatment market?

In the year 2025, the industry size of pulmonary fibrosis treatment is estimated at USD 3.42 billion. Read More

Pulmonary Fibrosis Treatment Market Trends

Growth Drivers

Risk Factors Associated With Pulmonary Fibrosis to Drive the Market Growth
There are certain risk factors which lead to the occurrence of pulmonary fibrosis. These include geriatric population, smoking, exposure to toxins, cancer treatments along with some genetic factors. According to the National Health Service (NHS) in UK, idiopathic pulmonary fibrosis (IPF) commonly affects people between the ages of 70 and 75 years, and it rarely occurs among people under the age of 50 years. Moreover, it states that about 1 in 20 people with IPF have a family history of the disease. These risk factors are estimated to drive the pulmonary fibrosis treatment market growth in coming years.
Increase in Cigarette Smoking Population to Drive the Market Growth
The increasing number of people who smoke is a major concern which results in several diseases of the lungs, including pulmonary fibrosis. According to Centers for Disease Prevention and Control, around 13.7% of all adults, i.e., 34.2 million people were reported to smoke cigarettes in the United States in 2018, out of which, 15.6% were men and 12.0% were women. This is predicted to raise the demand for drugs for pulmonary fibrosis and thereby boost the growth of the pulmonary fibrosis treatment market during the forecast period.

Challenges

Limited Availability of Approved Drugs to Restrict the Market Growth
Presently, only a few drugs have been received approval by the FDA and other regulatory bodies for the treatment of pulmonary fibrosis. There are only two approved drugs as of now, pirfenidone and nintedanib. This is estimated to limit the market growth. More research and development in the field is required in order to expand the pulmonary fibrosis treatment market size.

Pulmonary Fibrosis Treatment Market: Key Insights

As per the Pulmonary Fibrosis Foundation, the disease affects about 1 out of 200 adults above the age of 70 years in the United States. Moreover, around 50,000 new cases of pulmonary fibrosis are diagnosed in the country every year.

The pulmonary fibrosis drugs market is anticipated to record a significantly high CAGR over the forecast period, i.e., 2020-2028. The market is segmented by drug and by region, out of which, the drug segment is further bifurcated into pirfenidone and nintedanib. The segment for pirfenidone is anticipated to hold the largest share in the pulmonary fibrosis drugs market on account of increased usage of the drug ever since it received approval by the Food and Drug Administration (FDA). Esbriet is a pirfenidone drug manufactured by Genentech, Inc. and approved by the U.S. FDA in 2014 in the United States. The drug is available as oral dosage in the form of either capsules or tablets. The most common adverse reactions consist of rash, nausea, headache, fatigue, dizziness, insomnia and upper respiratory tract infections. The segment for nintedanib is predicted to grow at a substantial rate as well, owing to the high demand for the drug. Ofev is a nintedanib drug which received FDA approval in 2014 in the United States. This drug, developed by Boehringer Ingelheim International GmbH, is in the form of capsules for oral use. Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Base Year	2024
Forecast Year	2025-2037
CAGR	6.2%
Base Year Market Size (2024)	USD 3.25 billion
Forecast Year Market Size (2037)	USD 7.1 billion
Regional Scope	North America (U.S., and Canada) Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific) Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Latin America (Mexico, Argentina, Brazil, Rest of Latin America) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Why is the pulmonary fibrosis treatment sector gaining traction in near future?

Pulmonary Fibrosis Treatment Market size was over USD 3.25 billion in 2024 and is anticipated to cross USD 7.1 billion by 2037, growing at more than 6.2% CAGR during the forecast period i.e., between 2025-2037.

Which region dominated the majority of pulmonary fibrosis treatment industry share?

Asia Pacific industry is predicted to dominate majority revenue share by 2037, driven by growing presence of leading companies involved in research and development activities for the manufacturing of effective drugs.

Who are the major pulmonary fibrosis treatment players?

The major players in the market are Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, MediciNova, Inc., Genentech, Inc., Cipla Inc., Biogen and Galapagos NV.

Pulmonary Fibrosis Treatment Market Trends